Raymond James Financial Services Advisors, Inc. Reata Pharmaceuticals Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	BUY	$30.85 - $93.17 $166,466 - $502,745	5,396 New	5,396 $490,000
Q4 2021 Feb 08, 2022	SELL	$25.61 - $110.96 $62,949 - $272,739	-2,458 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$100.0 - $143.02 $20,600 - $29,462	206 Added 9.15%	2,458 $247,000
Q2 2021 Aug 11, 2021	SELL	$78.27 - $151.29 $31,229 - $60,364	-399 Reduced 15.05%	2,252 $319,000
Q1 2021 May 14, 2021	BUY	$94.25 - $132.81 $80,112 - $112,888	850 Added 47.2%	2,651 $264,000
Q4 2020 Feb 12, 2021	BUY	$102.03 - $184.62 $183,756 - $332,500	1,801 New	1,801 $223,000
Q3 2020 Nov 04, 2020	SELL	$93.53 - $163.34 $203,427 - $355,264	-2,175 Closed	0 $0
Q2 2020 Jul 17, 2020	BUY	$126.3 - $176.56 $274,702 - $384,018	2,175 New	2,175 $339,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account